Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units
- 114 Downloads
Physicochemical incompatibility (PCI) between drugs infused together is frequent, but under-recognized. PCI can lead to drug inactivity, catheter occlusion, embolism or inflammatory reactions. The aims of this work were to identify most frequent and relevant drug incompatibilities and to review and develop strategies for their prevention.
This was an observational prospective survey conducted between January and March 2015 in an intensive care unit (ICU) and in September 2014 in a hematology sterile unit (HSU). Drugs administered to patients were recorded and their compatibility assessed based on published compatibility data.
Drug incompatibilities accounted for 12% (23/189) and 17% (116/686) of drug pairs infused in the ICU and the HSU, respectively. Pantoprazole was the most frequent drug implied in PCI. Regarding drug classes, anti-infective agents and gastrointestinal drugs were the most frequently implied. Among the incompatible pairs, 78% and 61% implicated a drug with extreme pH in the ICU and HSU, respectively. The tools proposed to reduce the frequency of PCI included: compatibility cross-tables, labeling of drugs with extreme pH and optimized administration schedules.
Given the frequency and the potential for severe consequences of PCI, pharmacists have a role to play in raising awareness of nurses and practitioners, and proposing adequate tools and solutions to reduce their incidence.
KeywordsDrug incompatibilities Intravenous therapy Adverse drug events prevention Pharmacist Intensive care unit
Marion Nouvel, Anne-Gaëlle Caffin, Géraldine Iroir, Bérengère Clerc, Carole Dugrenier, Corinne Béal, Gilles Salles, Catherine Rioufol.
- 4.Jack T, Boehne M, Brent BE et al (2012) In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med 38:1008–1016. https://doi.org/10.1007/s00134-012-2539-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Research Center for Drug Evaluation and Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin) 9/2007. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm. Accessed 24 Oct 2017
- 12.Infostab Stabilis 4.0. http://www.stabilis.org/. Accessed 24 Oct 2017
- 13.CNHIM Thériaque. http://www.theriaque.org/apps/contenu/accueil.php. Accessed 24 Oct 2017
- 14.Trissel LA (2013) Handbook on injectable drugs, 17th edn. American Soc. of Health-System Pharmacists, BethesdaGoogle Scholar
- 15.Cayo L (2011) Compatibility of commonly used IV drugs. Pharm Pract News 67–72Google Scholar
- 16.Hôpitaux Universitaires de Genève (2012) Compatibilités des médicaments injectables administrés en Y. https://pharmacie.hug-ge.ch/infomedic/utilismedic/HUG_CompatAdm_DCI.pdf. Accessed 24 Oct 2017
- 17.Neveu N (2012) Administrations parentérales en Unité d’Hématologie Soins Intensifs: incompatibilités physico-chimiques et optimisations. PharmD, Université Joseph Fourier - Faculté de Pharmacie de GrenobleGoogle Scholar
- 24.Trissel LA (2001) Drug stability and compatibility issues in drug delivery. In: Handbook on injectable drugs, 11th edn. ASHP Publishing Department, BethesdaGoogle Scholar